Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... July 12 to take part in the first half of “Integrative Biotechnology,” an ... a partnership established in summer 2014, this course combines students from both universities ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... provide new insights on mechanics of fecal microbiota transplantation in C. difficile patients. ... the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for ...
(Date:6/30/2015)... ... 30, 2015 , ... The maximum number of shares proposed to be purchased ... shares of unvested restricted stock). On June 29, 2015, the last trading day prior ... reported on the OTCBB was $2.29 per share. , The tender offer will expire ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... DIEGO, April 14 XIFIN Inc., the ... diagnostic laboratories, announced today that XIFIN,s CEO ... at the Executive War College Conference in ... attendance will be senior executives, laboratory administrators ...
... to begin after markets close at 2:00 p.m. PT (5:00 ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through ... first quarter 2009 financial results for the period ended April ... 2009.A conference call to review the results will begin at ...
... N.C., April 14 Pharmaceutical Institute (PI), the ... pharmaceutical and biotech industry, today announced the release ... Markets Excellence(TM) . The series was developed ... leaders from 17 large and midsize pharmaceutical and ...
Cached Biology Technology:XIFIN Inc. CEO to Speak at Executive War College Conference 2XIFIN Inc. CEO to Speak at Executive War College Conference 3Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 2Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 3Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 2Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 3
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
(Date:6/15/2015)... , June 16, 2015 According ... Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, ... to 2020" published by MarketsandMarkets, The Natural Language Processing ... a CAGR of 18.4% for the forecast period 2015-2020. ...   46 F igures spread   through 155 ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... and other astute observers of nature have long known that ... the biochemical mechanisms that control this nightly stem elongation, common ... biologistsuntil now. In this week,s early online publication of ... California, San Diego report their discovery of a protein complex ...
... Tel Aviv Stem cells from early embryos can be ... revive and repair different areas of the body. Therapies based ... treatment of diabetes, but have been held back by medical ... are capitalizing on the "memories" of stem cells generated from ...
... Several types of cancer, including stomach, liver and colon, ... scientists have theorized that differences in lifestyle, such as diet ... suggests that the differences are rooted in basic biological differences ... new study from MIT shows that treating male mice with ...
Cached Biology News:Biologists discover an 'evening' protein complex that regulates plant growth 2Biologists discover an 'evening' protein complex that regulates plant growth 3Biologists discover an 'evening' protein complex that regulates plant growth 4Biologists discover an 'evening' protein complex that regulates plant growth 5Stem cell 'memory' can boost insulin levels 2Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: